FCCC LOGO Faculty Publications
Zou ZW , Ma C , Medoro L , Chen L , Wang B , Gupta R , Liu T , Yang XZ , Chen TT , Wang RZ , Zhang WJ , Li PD
LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells
Oncotarget. 2016 Sep 20;7(38) :61741-61754
PMID: 27557514    PMCID: PMC5308687   
Back to previous list
Long noncoding RNAs play a vital role in diverse biological processes such as embryonic development, cell growth, and tumorigenesis. In this study, we report that LncRNA ANRIL, which encodes a 3834-nt RNA that contains 19 exons at the antisense orientation of the INK4B-ARF-INK4A gene cluster, generally up-regulated in nasopharyngeal carcinoma [1]. In a cohort of 88 NPC patients, ANRIL was highly expressed in advanced-stage cancer. Multivariate analyses revealed that ANRIL expression could serve as an independent predictor of overall survival (P = 0.027) and disease-free survival (P = 0.033). Further investigation showed that knockdown of ANRIL significantly repressed NPC cell proliferation and transformation. We also found that ANRIL could induce the percentage of side population cells (SP cells) in NPC. To meet the urgent needs of energy provision, ANRIL can also reprogram glucose metabolism via increasing glucose uptake for glycolysis, which was regulated by the mTOR signal pathway to affect the expression of essential genes in glycolysis. We concluded that ANRIL could promote NPC progression via increasing cell proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. Our results also suggested that ANRIL may serve as a novel diagnostic or prognostic biomarker and a candidate target for new therapies in NPC.
1949-2553 Zou, Zhen Wei Ma, Charlie Medoro, Lorraine Chen, Lili Wang, Bin Gupta, Roohi Liu, Ting Yang, Xian Zi Chen, Tian Tian Wang, Ruo Zhen Zhang, Wen Jie Li, Pin Dong P30 CA006927/CA/NCI NIH HHS/United States Journal Article United States Oncotarget. 2016 Sep 20;7(38):61741-61754. doi: 10.18632/oncotarget.11437.